Please ensure Javascript is enabled for purposes of website accessibility

Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Sinking Today

By Keith Speights – Aug 24, 2021 at 11:45AM

Key Points

  • There wasn't any news behind the declines for several leading COVID-19 vaccine stocks.
  • Instead, investors appear to be taking profits off the table after nice jumps on Monday following the FDA's full approval of the Pfizer-BioNTech COVID-19 vaccine.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The euphoria over full FDA approval of the Pfizer-BioNTech vaccine appears to be waning.

What happened

Shares of several top COVID-19 vaccine makers were sinking on Tuesday. Pfizer (PFE 1.29%) stock was down 2.7% as of 11:09 a.m. EDT. Shares of Pfizer's partner, BioNTech (BNTX 2.08%), were falling 7%. Moderna (MRNA 1.59%) stock was tumbling 5.4%. Novavax (NVAX -2.02%) was the biggest loser with its shares declining 8.1%.

Why did these vaccine stocks slump? It wasn't because of any bad news related to COVID-19 vaccines. None of the companies issued press releases that would explain the declines. Instead, we're probably just seeing downward pressure on prices as investors take some profits off the table after a nice jump for each of the stocks on Monday following the U.S. Food and Drug Administration full approval of the Pfizer-BioNTech vaccine.

A healthcare professional giving a shot in the arm of a patient.

Image source: Getty Images.

So what

It's really not all that surprising that these stocks would give up much of the gains from Monday. FDA approval for the Pfizer-BioNTech vaccine was fully expected.

Also, the approval doesn't impact Pfizer or BioNTech financially over the short term. The U.S. had already ordered 500 million doses of the companies' COVID-19 vaccine, Comirnaty, plus another 500 million doses to donate to other countries.

If Pfizer and BioNTech didn't receive any near-term material benefits from the full FDA approval, the other vaccine makers certainly didn't either. Moderna hasn't won full FDA approval of its COVID-19 vaccine yet, although it's practically a slam dunk that the approval will be on the way. Novavax hasn't even submitted for U.S. Emergency Use Authorization of its COVID-19 vaccine candidate yet.

Now what

Pfizer, BioNTech, and Moderna hope to win EUAs for their vaccines in younger children within the next few months. The companies also will pursue full FDA approvals in these age groups. Novavax plans to file for EUA of its COVID-19 vaccine in the fourth quarter, with submissions in the U.K. and Europe coming even sooner.

Perhaps the most important thing to watch with all of these stocks is the supply deals they secure for 2022 and beyond. All four companies have already signed some supply agreements for delivery beginning next year. 

Keith Speights owns shares of Pfizer. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Stock Quote
Pfizer
PFE
$50.13 (1.29%) $0.64
Novavax Stock Quote
Novavax
NVAX
$16.49 (-2.02%) $0.34
Moderna Stock Quote
Moderna
MRNA
$175.91 (1.59%) $2.76
BioNTech Se Stock Quote
BioNTech Se
BNTX
$167.02 (2.08%) $3.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
349%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.